Bioequivalence: tried and tested.
作者信息
Schall R, Endrenyi L
出版信息
Cardiovasc J Afr. 2010 Mar-Apr;21(2):69-71.
Abstract
摘要
相似文献
1
Bioequivalence: tried and tested.
Cardiovasc J Afr. 2010 Mar-Apr;21(2):69-71.
2
[Bioequivalence studies of pharmaceutical preparations].
Cas Lek Cesk. 2007;146(5):431-3.
3
Japanese guidance on bioavailability and bioequivalence.
Eur J Drug Metab Pharmacokinet. 2000 Jan-Mar;25(1):28-31. doi: 10.1007/BF03190053.
4
[Generic drugs, bioavailability, and bioequivalence].
Gac Med Mex. 1998 Jul-Aug;134(4):491-4.
5
New bioequivalence studies: individual bioequivalence and population bioequivalence.
Yakugaku Zasshi. 2000 Nov;120(11):1201-8. doi: 10.1248/yakushi1947.120.11_1201.
6
Evaluating the bioequivalence of clopidogrel generic formulations.
Curr Med Res Opin. 2015 May;31(5):861-4. doi: 10.1185/03007995.2015.1028912. Epub 2015 Apr 1.
7
Comments on the note for guidance on bioavailability and bioequivalence in the European Union.
Methods Find Exp Clin Pharmacol. 1998;20 Suppl A:11.
8
[Bioavailability and bioequivalence. Studies in healthy volunteers].
An R Acad Nac Med (Madr). 1997;114(3):511-20.
9
International harmonization of bioequivalence studies and issues shared in common.
Yakugaku Zasshi. 2000 Nov;120(11):1193-200. doi: 10.1248/yakushi1947.120.11_1193.
10
Standard curve range for clinical sample analysis of oral bioavailability/bioequivalence studies: dilemma, introspection and strategies.
Bioanalysis. 2018 May 1;10(10):717-722. doi: 10.4155/bio-2018-0008. Epub 2018 May 17.
引用本文的文献
1
Novel Methods Developed in Bioequivalence Assays: Patent Review.
AAPS PharmSciTech. 2025 Mar 26;26(4):91. doi: 10.1208/s12249-025-03079-7.
2
Development and Validation of Discriminatory In-vitro Release Method for Intramammary Drug Product.
Pharm Res. 2024 Jan;41(1):129-139. doi: 10.1007/s11095-023-03609-7. Epub 2023 Oct 3.
本文引用的文献
1
Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.
Clin Pharmacokinet. 2009;48(11):725-43. doi: 10.2165/11318040-000000000-00000.
2
Bioequivalence approaches for highly variable drugs and drug products.
Pharm Res. 2008 Jan;25(1):237-41. doi: 10.1007/s11095-007-9434-x. Epub 2007 Sep 22.
3
A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Berlin, Germany, November 19, 2001.
Clin Ther. 2003 Jun;25(6):1654-69. doi: 10.1016/s0149-2918(03)80161-3.
4
A practical approach for evaluating population and individual bioequivalence.
Stat Med. 2000 Oct 30;19(20):2721-40. doi: 10.1002/1097-0258(20001030)19:20<2721::aid-sim541>3.0.co;2-8.
5
PhRMA perspective on population and individual bioequivalence.
J Clin Pharmacol. 2000 Jun;40(6):561-70. doi: 10.1002/j.1552-4604.2000.tb05980.x.
6
On population and individual bioequivalence.
Stat Med. 1993 Jun 30;12(12):1109-24. doi: 10.1002/sim.4780121202.
7
Variation in biologic availability of digoxin from four preparations.
N Engl J Med. 1971 Dec 9;285(24):1344-7. doi: 10.1056/NEJM197112092852403.
8
Biologic availability of digoxin tablets.
JAMA. 1973 Apr 9;224(2):243.
9
Consideration of individual bioequivalence.
J Pharmacokinet Biopharm. 1990 Jun;18(3):259-73. doi: 10.1007/BF01062202.
10
Therapeutic inequivalence.
Drug Saf. 1990;5 Suppl 1:114-9. doi: 10.2165/00002018-199000051-00018.
Zotero 插件